ArticleCancer discovery2025
The Germline and Somatic Origins of Prostate Cancer Heterogeneity.
Abstract read
In one paragraph
Article in Cancer discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Article
- Mechanisms of Progression and Challenges for Intervention in the Natural History of Early Prostate Cancer: A Narrative Review.Current oncology (Toronto, Ont.) · 2026Review
- Epigenetic modulation of prostate cancer disparities in men with African ancestry.Nature reviews. Urology · 2026Review
- Article
- Clinicogenomic Insights for Progression-Free Survival in Prostate Cancer.International journal of environmental research and public health · 2026Article
- A PHF19-YTHDC1 condensate switches EZH2-mediated gene suppression to activation for prostate cancer progression.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Germline-Somatic Liaison Dictates Cancer Subtypes via de novo Steroid Biosynthesis.Cancer discovery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
82 authors.
Takafumi N Yamaguchi *Ontario Institute for Cancer Research, Toronto, Canada.ORCID 0000-0003-1082-3871
Kathleen E Houlahan *Ontario Institute for Cancer Research, Toronto, Canada.ORCID 0000-0002-2273-2099
Helen Zhu *Ontario Institute for Cancer Research, Toronto, Canada.ORCID 0000-0002-5174-4582
Natalie Kurganovs *Ontario Institute for Cancer Research, Toronto, Canada.ORCID 0000-0002-8555-5528
Julie Livingstone *Ontario Institute for Cancer Research, Toronto, Canada.ORCID 0000-0002-8424-3768
Natalie S Fox *Ontario Institute for Cancer Research, Toronto, Canada.ORCID 0009-0001-7149-893X
Jiapei YuanDepartment of Pathology, UT Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-9381-8623
Jocelyn Sietsma PeningtonBioinformatics Division, Walter and Eliza Hall Institute, Parkville, Australia.ORCID 0000-0003-1561-0074
Chol-Hee JungMelbourne Bioinformatics, The University of Melbourne, Melbourne, Australia.ORCID 0000-0002-2992-3162
Tommer SchwarzBioinformatics Interdepartmental Program, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0003-1777-3280
Weerachai JaratlerdsiriLaboratory for Human Comparative and Prostate Cancer Genomics, Genomics and Epigenetics Division, Garvan Institute of Medical Research, Darlinghurst, Australia.ORCID 0000-0001-9100-1807
Job van RietDepartment of Medical Oncology, Erasmus University, Rotterdam, the Netherlands.ORCID 0000-0001-7767-7923
Peter GeorgesonMelbourne Bioinformatics, The University of Melbourne, Melbourne, Australia.ORCID 0000-0002-5096-4735
Stefano MangiolaAustralian Prostate Cancer Research Centre Epworth, Richmond, Australia.ORCID 0000-0001-7474-836X
Kodi TaraszkaDepartment of Computer Science, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0002-1921-2113
Robert LesurfOntario Institute for Cancer Research, Toronto, Canada.ORCID 0000-0001-7095-1491
Jue JiangLaboratory for Human Comparative and Prostate Cancer Genomics, Genomics and Epigenetics Theme, Garvan Institute of Medical Research, Darlinghurst, Australia.ORCID 0000-0003-0920-8310
Ken ChowAustralian Prostate Cancer Research Centre Epworth, Richmond, Australia.ORCID 0000-0001-5904-2684
Lawrence E HeislerOntario Institute for Cancer Research, Toronto, Canada.ORCID 0000-0002-1332-1802
Yu-Jia ShiahOntario Institute for Cancer Research, Toronto, Canada.ORCID 0009-0000-8365-9334
Susmita G RamanandDepartment of Pathology, UT Southwestern Medical Center, Dallas, Texas.ORCID 0000-0001-9711-0342
Michael J ClarksonAustralian Prostate Cancer Research Centre Epworth, Richmond, Australia.ORCID 0009-0001-8586-0338
Anne NguyenAustralian Prostate Cancer Research Centre Epworth, Richmond, Australia.ORCID 0009-0004-5986-8530
Shadrielle Melijah G EspirituOntario Institute for Cancer Research, Toronto, Canada.ORCID 0009-0002-0584-0626
Ryan StuchberyAustralian Prostate Cancer Research Centre Epworth, Richmond, Australia.ORCID 0000-0003-3670-2023
Richard JovelinOntario Institute for Cancer Research, Toronto, Canada.ORCID 0009-0006-7656-8438
Vincent HuangOntario Institute for Cancer Research, Toronto, Canada.ORCID 0000-0002-6504-179X
Connor BellDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-2148-2972
Edward O'ConnorDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0003-3758-8576
Patrick J McCoyAustralian Prostate Cancer Research Centre Epworth, Richmond, Australia.ORCID 0000-0001-9412-110X
Christopher M LalansinghOntario Institute for Cancer Research, Toronto, Canada.ORCID 0000-0003-1225-0931
Marek CmeroAustralian Prostate Cancer Research Centre Epworth, Richmond, Australia.ORCID 0000-0001-7783-5530
Adriana SalcedoOntario Institute for Cancer Research, Toronto, Canada.ORCID 0000-0002-3365-2705
Eva K F ChanSt Vincent's Clinical School, University of New South Wales, Randwick, Australia.ORCID 0000-0002-6104-3763
Lydia Y LiuOntario Institute for Cancer Research, Toronto, Canada.ORCID 0000-0001-6026-3169
Phillip D StrickerDepartment of Urology, St. Vincent's Hospital Sydney, Darlinghurst, Australia.ORCID 0000-0002-0934-0656
Vinayak BhandariOntario Institute for Cancer Research, Toronto, Canada.ORCID 0000-0003-0265-0835
Riana M S BornmanSchool of Health Systems and Public Health, University of Pretoria, Pretoria, South Africa.ORCID 0000-0003-3975-2333
Dorota H S SendorekOntario Institute for Cancer Research, Toronto, Canada.ORCID 0000-0001-6199-246X
Andrew LonieMelbourne Bioinformatics, The University of Melbourne, Melbourne, Australia.ORCID 0000-0002-2006-3856
Stephenie D ProkopecOntario Institute for Cancer Research, Toronto, Canada.ORCID 0000-0001-7936-8577
Michael FraserOntario Institute for Cancer Research, Toronto, Canada.ORCID 0000-0002-9303-9363
Justin S PetersAustralian Prostate Cancer Research Centre Epworth, Richmond, Australia.ORCID 0009-0002-8353-259X
Adrien FoucalOntario Institute for Cancer Research, Toronto, Canada.ORCID 0000-0003-1619-0753
Shingai B A MutambirwaDepartment of Urology, Sefako Makgatho Health Science University, Medunsa, South Africa.ORCID 0000-0003-1414-0218
Lachlan McintoshBioinformatics Division, Walter and Eliza Hall Institute, Parkville, Australia.ORCID 0009-0005-3543-0259
Michèle OrainResearch Centre of CHU de Québec-Université Laval, Québec City, Canada.ORCID 0000-0002-9779-1851
Matthew WakefieldBioinformatics Division, Walter and Eliza Hall Institute, Parkville, Australia.ORCID 0000-0001-6624-4698
Valérie PicardDivision of Urology and Research Centre of CHU de Québec-Université Laval, Québec City, Canada.ORCID 0000-0002-8414-863X
Daniel J ParkMelbourne Bioinformatics, The University of Melbourne, Melbourne, Australia.ORCID 0000-0002-6354-0931
Hélène HovingtonDivision of Urology and Research Centre of CHU de Québec-Université Laval, Québec City, Canada.ORCID 0000-0002-5500-5648
Michael KergerAustralian Prostate Cancer Research Centre Epworth, Richmond, Australia.ORCID 0000-0002-9745-728X
Alain BergeronDivision of Urology and Research Centre of CHU de Québec-Université Laval, Québec City, Canada.ORCID 0000-0002-2875-0773
Veronica SabelnykovaOntario Institute for Cancer Research, Toronto, Canada.ORCID 0000-0003-1303-1060
Ji-Heui SeoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-7280-3334
Mark M PomerantzDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0003-4914-1157
Noah ZaitlenDepartment of Neurology, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0002-3553-3670
Sebastian M WaszakCentre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, University of Oslo and Oslo University Hospital, Oslo, Norway.ORCID 0000-0003-3042-9521
Alexander GusevDivision of Population Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-7980-4620
Louis LacombeDivision of Urology and Research Centre of CHU de Québec-Université Laval, Québec City, Canada.ORCID 0000-0003-4811-0308
Yves FradetDivision of Urology and Research Centre of CHU de Québec-Université Laval, Québec City, Canada.ORCID 0000-0002-7581-2500
Andrew RyanTissuPath Specialist Pathology Services, Mount Waverley, Australia.ORCID 0000-0002-5337-4714
Amar U KishanJonsson Comprehensive Cancer Centre, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0002-4836-8483
Martijn P LolkemaDepartment of Computer Science, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0003-0466-2928
Joachim WeischenfeldtBiotech Research & Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-3917-5524
Bernard TêtuResearch Centre of CHU de Québec-Université Laval, Québec City, Canada.ORCID 0000-0003-2771-2641
Anthony J CostelloAustralian Prostate Cancer Research Centre Epworth, Richmond, Australia.ORCID 0000-0003-3083-1799
Vanessa M HayesSt Vincent's Clinical School, University of New South Wales, Randwick, Australia.ORCID 0000-0002-4524-7280
Rayjean J HungProsserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Toronto, Canada.ORCID 0000-0002-4486-7496
Housheng H HeDepartment of Medical Biophysics, University of Toronto, Toronto, Canada.ORCID 0000-0003-2898-3363
John D McPhersonOntario Institute for Cancer Research, Toronto, Canada.ORCID 0000-0001-8049-9347
Bogdan PasaniucJonsson Comprehensive Cancer Centre, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0002-0227-2056
Theodorus van der KwastPrincess Margaret Cancer Centre, University Health Network, Toronto, Canada.ORCID 0000-0001-8640-5786
Anthony T PapenfussMelbourne Bioinformatics, The University of Melbourne, Melbourne, Australia.ORCID 0000-0002-1102-8506
Matthew L FreedmanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-0151-1238
Bernard J PopeDepartment of Surgery, The University of Melbourne, Parkville, Australia.ORCID 0000-0002-4840-1095
Robert G BristowDepartment of Medical Biophysics, University of Toronto, Toronto, Canada.ORCID 0000-0002-8553-9544
Ram S ManiDepartment of Pathology, UT Southwestern Medical Center, Dallas, Texas.ORCID 0000-0003-3552-7905
Niall M Corcoran *Australian Prostate Cancer Research Centre Epworth, Richmond, Australia.ORCID 0000-0003-4483-6945
Jüri Reimand *Ontario Institute for Cancer Research, Toronto, Canada.ORCID 0000-0002-2299-2309
Christopher M Hovens *Australian Prostate Cancer Research Centre Epworth, Richmond, Australia.ORCID 0000-0002-0610-1289
Paul C Boutros *Department of Human Genetics, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0003-0553-7520
Funding
Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Robert Damoiseaux · 1985 to 2026
$134.5MMethods for Genome-wide Association Studies in Admixed PopulationsR01HG006399 · NHGRI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI PRICE, ALKES L · 2011 to 2024
$6.3MOptimizing imputation for diverse populations in a distributed frameworkU01HG009080 · NHGRI · STANFORD UNIVERSITY · PI KENNY, EIMEAR ELIZABETH · 2016 to 2020
$5.2MAdvancing method benchmarking and data sharing through crowd-sourced competitions in cancer researchU24CA248265 · NCI · SAGE BIONETWORKS · PI BOUTROS, PAUL CHRISTOPHER, VARMA, SUSHEEL · 2020 to 2024
$4.1MImproved methods for inference of genotype-specific response to environmental toxinsR01ES029929 · NIEHS · PRINCETON UNIVERSITY · PI AYROLES, JULIEN, CLARK, ANDREW G · 2019 to 2023
$3.6M(PQ3) A functional genomic approach to identification and interpretation of germline-tumor genetic interactionsR01CA227237 · NCI · DANA-FARBER CANCER INST · PI GUSEV, ALEXANDER, ZAITLEN, NOAH A · 2018 to 2022
$3.5MElucidation of the genetic mechanisms driving prostate tumorigenesis through integrative computational and functional approachesR01CA251555 · NCI · DANA-FARBER CANCER INST · PI FREEDMAN, MATTHEW L, PASANIUC, BOGDAN · 2021 to 2025
$3.4M(8) Genetics of Immune Related Adverse Events and Response to ImmunotherapyR01CA227466 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ZIV, ELAD · 2018 to 2023
$3.3MVirginia-UCLA-Toronto Biomarker Characterization CenterU2CCA271894 · NCI · OLD DOMINION UNIVERSITY · PI OLIVER John SEMMES · 2022 to 2026
$3.2MGenomic Approaches to Population Health in Multi-Ethnic Hospital SystemsR01HG011345 · NHGRI · UNIVERSITY OF COLORADO DENVER · PI ARBOLEDA, VALERIE A, GIGNOUX, CHRISTOPHER R · 2020 to 2023
$3.1MGermline Determinants of Prostate Cancer EvolutionR01CA270108 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PAUL T. SPELLMAN · 2023 to 2026
$2.9M3D genome architecture and the origins of recurrent genomic rearrangements in prostate cancerR01CA245294 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI MANI, RAM SHANKAR · 2020 to 2024
$1.9MDOD Prostate Cancer Research Program (PCRP) W81XWH2210247National Cancer Institute (NCI) R01CA270108NCI NIH HHS P30 CA016042NCI NIH HHS R01 CA227237NCI NIH HHS R01 CA227466NCI NIH HHS R01 CA245294NCI NIH HHS R01 CA251555NCI NIH HHS R01 CA270108NCI NIH HHS U24 CA248265NCI NIH HHS U2C CA271894NHGRI NIH HHS R01 HG006399NHGRI NIH HHS R01 HG011345NHGRI NIH HHS U01 HG009080NIEHS NIH HHS R01 ES029929
Abstract
significanceThis study uncovered 223 recurrently mutated driver regions using the largest cohort of prostate tumors to date. It reveals associations between germline SNPs, somatic drivers, and tumor aggression, offering significant insights into how prostate tumor evolution is shaped by germline factors and the timing of somatic mutations.
Indexed as
Genetic HeterogeneityGerm-Line MutationProstatic NeoplasmsHumansMaleMutationPolymorphism, Single Nucleotide
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.